Wang Zhong, Lecane Philip S, Thiemann Patricia, Fan Qing, Cortez Cecilia, Ma Xuan, Tonev Danielle, Miles Dale, Naumovski Louie, Miller Richard A, Magda Darren, Cho Dong-Gyu, Sessler Jonathan L, Pike Brian L, Yeligar Samantha M, Karaman Mazen W, Hacia Joseph G
Pharmacyclics, Inc., Sunnyvale, California, USA.
Mol Cancer. 2007 Jan 19;6:9. doi: 10.1186/1476-4598-6-9.
Sapphyrin analogues and related porphyrin-like species have attracted attention as anticancer agents due to their selective localization in various cancers, including hematologic malignancies, relative to surrounding tissues. Sapphyrins are electron affinic compounds that generate high yields of singlet oxygen formation. Although initially explored in the context of photodynamic therapy, sapphyrins have intrinsic anticancer activity that is independent of their photosensitizing properties. However, the mechanisms for their anticancer activity have not been fully elucidated.
We have prepared a series of hydrophilic sapphyrins and evaluated their effect on proliferation, uptake, and cell death in adherent human lung (A549) and prostate (PC3) cancer cell lines and in an A549 xenograft tumor model. PCI-2050, the sapphyrin derivative with the highest in vitro growth inhibitory activity, significantly lowered 5-bromo-2'-deoxyuridine incorporation in S-phase A549 cells by 60% within eight hours and increased levels of reactive oxygen species within four hours. The growth inhibition pattern of PCI-2050 in the National Cancer Institute 60 cell line screen correlated most closely using the COMPARE algorithm with known transcriptional or translational inhibitors. Gene expression analyses conducted on A549 plateau phase cultures treated with PCI-2050 uncovered wide-spread decreases in mRNA levels, which especially affected short-lived transcripts. Intriguingly, PCI-2050 increased the levels of transcripts involved in RNA processing and trafficking, transcriptional regulation, and chromatin remodeling. We propose that these changes reflect the activation of cellular processes aimed at countering the observed wide-spread reductions in transcript levels. In our A549 xenograft model, the two lead compounds, PCI-2050 and PCI-2022, showed similar tumor distributions despite differences in plasma and kidney level profiles. This provides a possible explanation for the better tolerance of PCI-2022 relative to PCI-2050.
Hydrophilic sapphyrins were found to display promise as novel agents that localize to tumors, generate oxidative stress, and inhibit gene expression.
由于与周围组织相比,蓝宝石啉类似物及相关卟啉样物质能选择性地定位于包括血液系统恶性肿瘤在内的多种癌症中,因此作为抗癌剂受到关注。蓝宝石啉是电子亲和性化合物,能高产率地生成单线态氧。尽管最初是在光动力疗法的背景下进行研究,但蓝宝石啉具有独立于其光敏特性的内在抗癌活性。然而,其抗癌活性的机制尚未完全阐明。
我们制备了一系列亲水性蓝宝石啉,并评估了它们对贴壁生长的人肺癌(A549)和前列腺癌(PC3)细胞系以及A549异种移植肿瘤模型中细胞增殖、摄取和细胞死亡的影响。PCI - 2050是体外生长抑制活性最高的蓝宝石啉衍生物,在8小时内使S期A549细胞中的5 - 溴 - 2'-脱氧尿苷掺入量显著降低60%,并在4小时内提高活性氧水平。在国立癌症研究所60细胞系筛选中,PCI - 2050的生长抑制模式使用COMPARE算法与已知的转录或翻译抑制剂相关性最强。对用PCI - 2050处理的A549平台期培养物进行的基因表达分析发现,mRNA水平普遍下降,尤其影响短寿命转录本。有趣的是,PCI - 2050增加了参与RNA加工和转运、转录调控及染色质重塑的转录本水平。我们认为这些变化反映了旨在应对所观察到的转录本水平广泛降低的细胞过程的激活。在我们的A549异种移植模型中,尽管血浆和肾脏水平分布存在差异,但两种先导化合物PCI - 2050和PCI - 2022显示出相似的肿瘤分布。这为PCI - 2022相对于PCI - 2050具有更好的耐受性提供了一种可能的解释。
发现亲水性蓝宝石啉有望作为新型药物,能定位于肿瘤、产生氧化应激并抑制基因表达。